IRIX — IRIDEX Corporation

IRIDEX Corporation Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Total revenue for 2025 was $52.7 million, an 8% increase year-over-year. Q4 revenue grew 16% compared to the same quarter in 2024.
• Gross Profit: Gross profit was $5.5 million with a gross margin of 37%, down from 44% in 2024, primarily due to increased manufacturing costs and tariff impacts.
• Operating Expenses: Reduced by 22% year-over-year to $5.5 million.
• Net Loss: Narrowed to $200,000 ($0.01 per share) from a loss of $800,000 ($0.05 per share) in 2024.
• Adjusted EBITDA: Positive adjusted EBITDA of $817,000, an improvement from $611,000 in 2024.
• Cash Position: Cash and cash equivalents increased to $6 million, with a 71% reduction in cash usage year-over-year.

2. Strategic Updates and Business Highlights

• Operational Efficiency: Successful cost reduction initiatives led to a streamlined operation and positive cash flow from operations in Q4.
• Product Performance: Growth across all major product categories, including Cyclo G6 and PASCAL systems. Notable increases in sales of glaucoma probes and retina products.
• Market Expansion: Focus on leveraging the installed base of Cyclo G6 systems and targeting high-volume surgeons through new sales enablement tools.
• Cost Reduction Initiatives: Plans to relocate G&A functions and transition to lower-cost third-party manufacturing to improve gross margins.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected revenue between $51 million and $53 million, excluding Middle East sales due to ongoing conflict. This represents a growth of 1% to 5% compared to 2025.
• Seasonality: Anticipated cash generation improvements throughout 2026, with the first quarter typically being the lowest in revenue.

4. Bad News, Challenges, or Points of Concern

• Middle East Sales Impact: The ongoing conflict in Iran is materially affecting sales in the Middle East, which accounted for 5% of total revenue.
• Gross Margin Decline: The decrease in gross margin due to rising manufacturing costs and inventory write-downs is a concern for future profitability.
• International Challenges: Volatile conditions in Asia, particularly due to tariffs and currency pressures, are impacting sales forecasts and operational activities.

5. Notable Q&A Insights

• Middle East Revenue: Represents 5% of total revenue, highlighting its significance despite current challenges.
• Other Revenue Decline: The $2 million "other revenue" segment showed variability and is dependent on service product lines, indicating potential instability.
• G6 Pricing Trends: ASPs for G6 probes have increased, but there are concerns about pricing pressure in international markets.
• Retina Segment Growth: There is confidence in gaining market share, particularly with the PASCAL system, which is expected to drive growth as regulatory approvals are secured.

Overall, IRIDEX Corporation demonstrated a positive trajectory in Q4 2025, achieving key financial milestones while navigating external challenges, particularly in the Middle East and Asia. The company remains focused on strategic growth initiatives and operational efficiency to enhance profitability moving forward.